[8-K] MiNK Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

MiNK Therapeutics, Inc. (Nasdaq: INKT) filed an 8-K to highlight new clinical evidence supporting its allogeneic invariant natural killer T-cell therapy, agenT-797.

• Landmark peer-reviewed case: Nature’s Oncogene published a complete, durable remission (>2 years) in a patient with metastatic, treatment-refractory testicular cancer after a single agenT-797 infusion plus nivolumab (trial NCT05108623). No CRS or GVHD observed; donor iNKT cells persisted up to six months.
• Phase 2 gastric cancer signals: At the 2025 AACR Immuno-Oncology meeting, MiNK reported immune activation, increased tumor infiltration and early tumour-control signals in second-line gastric cancer patients previously refractory to checkpoint inhibitors; several patients lived >12 months post-treatment.
• Additional case report: A separate Oncogene paper detailed a metastatic gastric cancer patient who achieved a 42 % tumour reduction and >9 months progression-free survival following a single agenT-797 dose with nivolumab.
• Pipeline momentum: The ongoing Phase 2 gastric cancer study (NCT06251973) is actively enrolling, with further read-outs expected “in upcoming months.”

The filing contains forward-looking statements and reminds investors of risk factors detailed in MiNK’s March 31 2025 10-Q.

Positive

• Peer-reviewed complete and durable remission in refractory testicular cancer strengthens clinical evidence for agenT-797.
• Early Phase 2 gastric cancer data show immune activation and >12-month survival in several patients, indicating potential efficacy.
• No CRS or GVHD safety signals reported, supporting the tolerability of the allogeneic iNKT platform.
• Ongoing Phase 2 trial actively enrolling with additional data expected soon, providing near-term catalysts.

Negative

• None.

Insights

Biotech Equity Analyst

TL;DR: Peer-reviewed complete remission and early Phase 2 signals strengthen agenT-797’s clinical credibility, a clear incremental positive for INKT.

The publication of a durable remission in heavily pre-treated testicular cancer provides independent validation in a top-tier journal—critical for small-cap biotech credibility. Safety (no CRS/GVHD) and persistence data de-risk the allogeneic iNKT platform. Gastric cancer data, though early, show biological activity and survival extension, supporting the ongoing Phase 2 trial. While no financials are disclosed, clinical momentum can improve partnership or capital-raising prospects. Impact: positive but not transformational until larger datasets arrive.

Small-Cap Portfolio Manager

TL;DR: Event is impactful; peer-review plus survival data may catalyze sentiment and liquidity in INKT shares.

For micro-cap therapeutics, third-party validation often drives outsized stock moves. Publishing in Oncogene and presenting at AACR both expand investor and clinician awareness. Mention of extended survival beyond 12 months addresses a key endpoint in gastric cancer. Absence of safety red flags mitigates risk perception. However, with only case-level data disclosed, valuation re-rating potential hinges on forthcoming Phase 2 read-outs. Net impact today is positive and could aid follow-on financing.

false000184022900018402292025-07-112025-07-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 11, 2025

MiNK Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40908	82-2142067
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
149 Fifth Avenue Suite 500
New York, New York				10010
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 212 994-8250

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		INKT		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On July 11, 2005, MiNK Therapeutics, Inc. (“MiNK” or the “Company”), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, announced the publication of another landmark case in Nature’s Oncogene describing a complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer, following treatment with agenT-797, MiNK’s allogeneic iNKT cell therapy. The publication, titled “Salvage therapy with allogeneic invariant natural killer T cells in a heavily pre-treated germ cell tumor,” presents a patient case from MiNK’s clinical trial (NCT05108623). The patient had progressed after multiple lines of therapy—including platinum-based chemotherapy, autologous stem cell transplant, and multiple immune checkpoint inhibitors (anti–PD-1, anti–CTLA-4, and anti–TIGIT)—and received a single infusion of agenT-797 alongside nivolumab. The patient achieved a complete clinical, radiologic, and biochemical remission, with no evidence of disease over two years later. Donor iNKT cells were detectable up to six months post-infusion, and treatment was well-tolerated with no cytokine release syndrome (CRS) or graft-versus-host disease (GVHD).

In addition, at the 2025 inaugural AACR Immuno-Oncology meeting, MiNK presented data from its Phase 2 trial in 2L gastric cancer, demonstrating immune activation, increased tumor infiltration, and early signals of tumor control in patients previously refractory to checkpoint inhibitors. Extended survival beyond 12 months was observed in several patients. In a separate peer-reviewed case report published in Oncogene, which described a patient with metastatic gastric cancer who achieved a 42% tumor reduction and more than nine months of progression-free survival following a single infusion of agenT-797 in combination with nivolumab.

The ongoing Phase 2 trial in gastric cancer (NCT06251973) is actively enrolling, with additional readouts expected in upcoming months.

Forward-Looking Statements

This current report contains “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on the Company’s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks and uncertainties, and actual results may differ materially from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, without limitation, the important risks detailed under the caption “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 and its other filings with the Securities and Exchange Commission. Any forward-looking statement made by the Company in this current report is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, the Company expressly disclaims any obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:	July 14, 2025	By:	/s/ Jennifer S. Buell, Ph.D.
			Presidend and CEO

FAQ

What did MiNK Therapeutics (INKT) announce on July 11 2025?

The company reported a complete, durable remission in a refractory testicular cancer patient treated with its iNKT therapy agenT-797 and shared additional Phase 2 gastric cancer data.

What is agenT-797?

agenT-797 is MiNK’s allogeneic, off-the-shelf invariant natural killer T-cell therapy designed to target solid tumors.

What were the testicular cancer results?

A single infusion of agenT-797 plus nivolumab led to a complete clinical, radiologic and biochemical remission lasting more than two years.

What Phase 2 gastric cancer data were presented?

MiNK observed immune activation, increased tumor infiltration and survival beyond 12 months in several checkpoint-refractory patients.

Are there ongoing trials for agenT-797?

Yes. The Phase 2 gastric cancer study (NCT06251973) is currently enrolling, with further read-outs expected in the coming months.

Were any safety issues reported?

No cytokine release syndrome or graft-versus-host disease was observed in the reported cases.